Literature DB >> 17052313

Chronic necrotizing pulmonary aspergillosis as a complication of pulmonary Mycobacterium avium complex disease.

Yoshihiro Kobashi1, Minoru Fukuda, Kouichiro Yoshida, Naoyuki Miyashita, Yoshihito Niki, Mikio Oka.   

Abstract

OBJECTIVE AND
BACKGROUND: To investigate the characteristic clinical features of chronic necrotizing pulmonary aspergillosis (CNPA) as a complication of pulmonary Mycobacterium avium complex (MAC) disease.
METHODS: Clinical analysis of nine cases without a history of old pulmonary tuberculosis in whom CNPA was found to be a complication during the follow-up period for MAC disease.
RESULTS: The average duration from the diagnosis of pulmonary MAC disease to the diagnosis of CNPA was 36.0 months. Five patients received antituberculous therapy including clarithromycin for pulmonary MAC disease, but this treatment was ineffective in most. A positive culture for Aspergillus spp. from sputum and a bronchoscopic specimen and clinical evidence of a chronic infective process were recognized in all cases at the time of detection of CNPA. Serological fungal examinations for anti-Aspergillus IgG antibody were initially negative and became positive in all cases during the follow-up period of pulmonary MAC disease. The presence of CNPA surrounding the cavity previously caused by MAC was characterized by local thickening of the cavity with a fungus ball and the appearance of an infiltration shadow surrounding the cavity. In most of the cases, CNPA was at first treated with oral itriconazole and then with i.v. infusion of micafungin, but the clinical efficacy was generally poor.
CONCLUSION: The results of this study showed that during the long follow-up period of patients with pulmonary MAC disease it is important to not only carry out serological examinations, but also perform radiological examinations using chest CT.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17052313     DOI: 10.1111/j.1440-1843.2006.00952.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  14 in total

1.  Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.

Authors:  Seong Mi Moon; Hye Yun Park; Byeong-Ho Jeong; Kyeongman Jeon; Soo-Youn Lee; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

2.  Clinical significance of Aspergillus species isolated from respiratory specimens in patients with Mycobacterium avium complex lung disease.

Authors:  K Furuuchi; A Ito; T Hashimoto; S Kumagai; T Ishida
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-09-17       Impact factor: 3.267

3.  Levels of Antibody against Glycopeptidolipid Core as a Marker for Monitoring Treatment Response in Mycobacterium avium Complex Pulmonary Disease: a Prospective Cohort Study.

Authors:  Seigo Kitada; Ryoji Maekura; Kenji Yoshimura; Keisuke Miki; Mari Miki; Yohei Oshitani; Kohei Nishida; Nobuhiko Sawa; Masahide Mori; Kazuo Kobayashi
Journal:  J Clin Microbiol       Date:  2016-12-28       Impact factor: 5.948

4.  Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts.

Authors:  M Hong Nguyen; Reia Jaber; Helen L Leather; John R Wingard; Benjamin Staley; L Joseph Wheat; Christina L Cline; Maher Baz; Kenneth H Rand; Cornelius J Clancy
Journal:  J Clin Microbiol       Date:  2007-06-27       Impact factor: 5.948

5.  Prevalence and risk factors for chronic co-infection in pulmonary Mycobacterium avium complex disease.

Authors:  Kohei Fujita; Yutaka Ito; Toyohiro Hirai; Takeshi Kubo; Kaori Togashi; Satoshi Ichiyama; Michiaki Mishima
Journal:  BMJ Open Respir Res       Date:  2014-08-28

Review 6.  Recent Advances in Diagnosing Chronic Pulmonary Aspergillosis.

Authors:  Takahiro Takazono; Koichi Izumikawa
Journal:  Front Microbiol       Date:  2018-08-17       Impact factor: 5.640

7.  The scab-like sign: A CT finding indicative of haemoptysis in patients with chronic pulmonary aspergillosis?

Authors:  Haruka Sato; Fumito Okada; Shunro Matsumoto; Hiromu Mori; Junji Kashiwagi; Eiji Komatsu; Toru Maeda; Haruto Nishida; Tsutomu Daa; Satoshi Ohtani; Kenji Umeki; Masaru Ando; Junichi Kadota
Journal:  Eur Radiol       Date:  2018-05-03       Impact factor: 7.034

8.  Risk factors for the development of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease.

Authors:  Byung Woo Jhun; Woo Jin Jung; Na Young Hwang; Hye Yun Park; Kyeongman Jeon; Eun-Suk Kang; Won-Jung Koh
Journal:  PLoS One       Date:  2017-11-30       Impact factor: 3.240

Review 9.  Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?

Authors:  Gemma E Hayes; Lilyann Novak-Frazer
Journal:  J Fungi (Basel)       Date:  2016-06-07

Review 10.  Pulmonary Mycobacterium parascrofulaceum Infection in a Patient with Chronic Progressive Pulmonary Aspergillosis: A Case Report and Literature Review.

Authors:  Hiroaki Ikegami; Kei Yamasaki; Toshinori Kawanami; Kazumasa Fukuda; Kentaro Akata; Midori Nakamura; Issei Ikushima; Yoko Fukuda; Shingo Noguchi; Kazuhiro Yatera
Journal:  Intern Med       Date:  2019-12-20       Impact factor: 1.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.